Flerie advances TOL2 drug trials after completing Toleranzia integration

Flerie has completed the integration of Toleranzia AB, marking a key step in its development pipeline. The company's flagship project, TOL2, is now entering a critical phase as clinical trials progress. Shareholders have also approved a bonus share issue, with allocations set for May 2026. TOL2 is a drug candidate aimed at treating myasthenia gravis, a rare autoimmune disease. Phase I/IIa clinical trials are currently underway, with Sweden and Germany leading the European testing sites. Market analysts have highlighted the drug's potential to change how the condition is managed.

The operational business of Toleranzia AB has been transferred to Bonsai Biotherapeutics AB, a subsidiary under Flerie. This move follows the company's decision to streamline its portfolio and focus on advancing TOL2. At the March 2026 annual general meeting, Flerie shareholders voted to issue bonus shares instead of distributing dividends. The funds saved will be redirected into product development. The record date for processing these bonus shares in shareholders' accounts is set for May 18, 2026.

The integration of Toleranzia AB is now complete, and TOL2 remains the central focus of Flerie's research efforts. With clinical trials progressing in two European countries and bonus shares allocated in May 2026, the company is positioning itself for the next stage of development. Shareholders have chosen to reinvest funds rather than receive dividends, signalling confidence in the project's future.